Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Targeted and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD59 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD59 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD59 Products |
| Gene Delivery | CD59 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for CDC assay development. |
View CD59 Products |
| Benchmark Ab | Anti-CD59 Recombinant Antibody Recombinant positive control for blocking and flow cytometry assays. |
View CD59 Products |
| Validator | CD59 siRNA Set For knockdown verification in functional validation assays. |
View CD59 Products |
| Related Target A | CD55 (Decay-Accelerating Factor) Synergistic complement regulatory protein (mCRP) co-expressed on cancer cells to evade complement attack. |
View CD55 Products |
| Related Target B | C5 (Complement Component 5) Downstream effector of the complement cascade; therapeutic target for complement-mediated hemolytic diseases. |
View C5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Post-Translational Modifications | HEK293 mammalian expression system preserves critical N- and O-glycosylations required for native epitope presentation. |
| Assay Interference & Toxicity | Ultra-low endotoxin levels (<1.0 EU/μg) prevent non-specific immune activation in primary cell assays. |
| Lack of Controls | Clinical-grade sequence-derived benchmark antibodies available for assay calibration. |
| False Positives | Sequence-verified siRNA sets included to confirm target specificity in cell-based assays. |
Live CD59 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD59 is bifurcated into two major strategies: complement inhibition and oncology sensitization. As a key membrane-bound complement regulatory protein (mCRP), CD59 restricts the formation of the membrane attack complex (MAC). In oncology, tumor cells overexpress CD59 to resist Complement-Dependent Cytotoxicity (CDC) induced by therapeutic monoclonal antibodies (e.g., Rituximab, Trastuzumab). Consequently, targeting CD59 with blocking antibodies or siRNA represents a powerful adjuvant strategy to restore therapeutic antibody efficacy.
Conversely, in complement-mediated inflammatory and hemolytic disorders (such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Age-Related Macular Degeneration (AMD)), therapeutic strategies focus on administering recombinant soluble CD59 (sCD59) or CD59-Fc fusion proteins to protect host cells from autologous complement attack. The next wave of R&D is focusing on bispecific molecules targeting both CD59 and CD55, as well as localized gene therapies delivering CD59 constructs to specific tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Blocking) | Academic Institutions, Biotech Startups | Solid Tumors, Hematological Malignancies | CDC Rescue Assays (Requires HEK293-expressed CD59 and stable overexpressing cell lines) |
| Recombinant Fusion Proteins (CD59-Fc) | Alexion Pharmaceuticals, Hemera Biosciences | Dry AMD, Paroxysmal Nocturnal Hemoglobinuria (PNH) | Binding Affinity (SPR/BLI) and MAC Inhibition Assays (Requires high-purity CD59 ECD-Fc) |
| Gene Therapy (AAV-CD59) | Janssen (Johnson & Johnson) | Geographic Atrophy (GA) secondary to AMD | In vitro expression validation (Requires sequence-verified CD59 antibodies and siRNA) |